This table lists all the major pharma collaborations, acquisitions and mergers during May 2013.
For an indepth analysis of these deals, read ‘Pharma deals during May 2013’
| Licensor acquired / licensee acquirer | Deal type | Product / technology | Headline ($m) |
| Bausch & Lomb/ Valeant | Company acquisition | Ophthalmology business | 8,700 |
| Warner Chilcott/ Actavis | Company acquisition | Branded medicines for women’s health, gastroenterology, derma | 8,500 |
| Theravance/ Elan Royalty | Participation | 21% of respiratory product royalties received by Theravance | 1,000 |
| Xellia/ Novo A/S | Company acquisition by Novo’s VC arm | API manufacturer and anti-infective products | 700 |
| AOP Orphan/ Elan | Company acquisition | Rare disease medicines $76m sales | 693 |
| Trevena/ Forest | Option to license + equity | TRV027 phase 2 acute heart failure + $30m equity | 460 |
| Omthera/ AstraZeneca | Company acquisition | Dyslipidemia therapy end phase III | 443 |
| Abide/ Merck & Co | Licence, collaboration | Targets for Type II diabetes – 3 products | 430 |
| Okairos/ GSK | Company acquisition | Vaccine platform technology | 325 |
| Newbridge/ Elan | 48 per cent company share | UAE based regional company $40m + $244m option for 52% | 284 |
| Inviragen/ Takeda | Company acquisition | Vaccines in phase I and II | 250 |
| Alexza/ Teva | Licence, supply US | Adasuve approved for acute agitation | 235* |
| EKOS/ BTG | Company acquisition | Device for treating blood clots | 220 |
| Therasphere/ BTG | Asset purchase | Treatment for liver cancer | 200 |
| Aradigm/ Grifols | Licence + equity | Inhaled ciprofloxacin phase III ready. 35 per cent of Aradigm ($26m) | 116 |
| Ambrx/ BMS | Licence | Develop and commercialise antibody drug conjugates | 112 |
| Elan/ Speranza | Product spin out | Product spin out ELND005 phase 2 CNS drug | 70** |
| Alvine/ Abbvie | Option to acquire | Phase II product for celiac disease | 70 |
| Cempra / Toyama | Licence, development | Solithromycin phase III | 70*** |
| Valeant / Actavis | Product acquisition | Metronidazole gel | 55 |
| Astellas / Amgen | Co-development / JV | 5 Amgen development products | ND*** |
| Nimbus / Shire | Co-development | Lysosomal storage disorder agents | ND |
Unless noted all transactions are for global rights
* US only
** Payment by Elan not Speranza
*** Japan only